Thu, Oct 2, 2014, 1:21 AM EDT - U.S. Markets open in 8 hrs 9 mins

Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

  • ricardouno ricardouno Nov 11, 2013 10:32 AM Flag

    ASH Abstracts

    Does anyone know what the below is about? It is listed in the Seattle Genetics press release about the upcoming ASH presentations:

    "Fucosylation Inhibitor, 2-fluorofucose, Inhibits NF-ĸB Activation and Vaso-occlusion in Transgenic Sickle Mice (Abstract #730, oral presentation at 7:00 p.m. ET) "

    Thanks in advance for any help.

    Ricardo

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • There are many articles recently regarding Fucosylation authored by researchers at Seattle Genetics. They have also been getting patents on their products. I gather it is all part if their engineered sugar technologies, but most of this research is well beyond my comprehension. The ASH abstract appears interesting as the SGN engineered sugar does markedly inhibit vaso occlusion in Sickle Cell mice without any toxicity observed .
      If you Google some of the key words their is a lot of recent literature but like I said , beyond my comprehension level.

 
SGEN
36.92-0.26(-0.70%)Oct 1 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.